Neuronetics (FRA:NRC) Long-Term Debt: €53.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NRC Neuronetics Inc FRA:NRC
60 GF Score
Price €1.50
GF Value €1.59
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Neuronetics Long-Term Debt?

Neuronetics FRA:NRC -1.64% 60 Long-Term Debt is €53.0 Mil as of Mar. 2026. GuruFocus rates FRA:NRC with a GF Score™ of 60/100 and a GF Value™ of €1.59 (Fairly Valued). The stock has 4 warning signs investors should review.

Neuronetics's Long-Term Debt for the quarter that ended in Mar. 2026 was €53.0 Mil.

Neuronetics's quarterly Long-Term Debt increased from Sep. 2025 (€56.0 Mil) to Dec. 2025 (€56.2 Mil) but then declined from Dec. 2025 (€56.2 Mil) to Mar. 2026 (€53.0 Mil).

Neuronetics's annual Long-Term Debt declined from Dec. 2023 (€54.4 Mil) to Dec. 2024 (€52.7 Mil) but then increased from Dec. 2024 (€52.7 Mil) to Dec. 2025 (€56.2 Mil).

Neuronetics  (FRA:NRC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Neuronetics Long-Term Debt Related Terms

Neuronetics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Neuronetics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics Long-Term Debt Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.27 21.55 54.36 52.67 56.20

Neuronetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.19 48.15 55.95 56.20 53.02
FRA:NRC
60GF Score
Neuronetics Inc FRA:NRC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €53.0 Mil mean?
Neuronetics (FRA:NRC) has a Long-Term Debt of €53.0 Mil as of Mar. 2026.
Is Neuronetics' Long-Term Debt too high?
Neuronetics' current Long-Term Debt is €53.0 Mil. Overall, Neuronetics has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Long-Term Debt compare to ZOMDF and OM?
Neuronetics' Long-Term Debt of €53.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Neuronetics's current Long-Term Debt is €53.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Fairly Valued. The stock's GF Value™ is €1.59, compared to a current price of €1.50 — trading 6% below its estimated fair value. The current Long-Term Debt is €53.0 Mil. Neuronetics' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Long-Term Debt is €53.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.50 is trading 6% below its estimated GF Value™ of €1.59. GuruFocus considers Neuronetics to be Fairly Valued.

Key valuation signals for FRA:NRC:

  • Long-Term Debt: €53.0 Mil
  • GF Value™: €1.59 vs. price of €1.50 (6% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
60GF Score

Get the complete analysis for FRA:NRC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price
€1.59
GF Value